Fashion Never Sleeps, So Dress Up for Bed
Canali jacket, $3,195, Canali.com, Ralph Lauren Purple Label scarf, $495, RalphLauren.com, Prounis necklace, $1,980, ProunisJewelry.com, Giuliva Heritage shirt, $970, GiulivaHeritage.com, Brioni pants, $1,370, Brioni.com, Loro Piana shoes, $925, US.LoroPiana.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
BrainScope Expands Board and Launches Advanced Deep Learning Platform to Enhance Brain Health Insights
BETHESDA, Md., June 11, 2025--(BUSINESS WIRE)--BrainScope®, a leader in AI-enabled EEG technology for brain health assessment, today announced the launch of its next-generation deep learning platform. BrainScope developed and has commercialized the first FDA-cleared AI/machine learning medical device in the field of neurology. Building on that foundation in machine learning, BrainScope's new capabilities enhance its ability to deliver fast, objective, and clinically actionable insights across brain health conditions including concussion, stroke, and early Alzheimer's detection. The integration of deep learning into BrainScope's proprietary platform marks a major leap forward in automated EEG analysis. BrainScope's new Large Neural Model platform brings many of the breakthroughs of Large Language Models (LLMs) to bear on EEG data, eliminating the need for specialized qEEG interpretation. This novel and proprietary approach enhances BrainScope's first-in-class machine learning foundation, with the potential to significantly expand its utility across clinical care, research, and biopharma by enabling the development of more refined biomarkers to support precision-driven clinical trial recruitment, early diagnosis, personalized treatment, and improved patient outcomes. To help guide the company as it expands its clinical program and commercial activities, BrainScope has announced key updates to its Board of Directors. Ralph Terkowitz, who has served on BrainScope's Board since 2023, has been elected Chairman. A former General Partner at ABS Capital Partners, Terkowitz brings decades of experience helping technology companies grow and scale. He also serves on the Board of The 10,000 Brains Project and is Co-Chairman of The Robert Packard Center for ALS Research at Johns Hopkins. In his expanded role, Terkowitz will guide BrainScope's continued growth and adoption of its AI-powered brain health platform. Also joining the Board are Mike Genau, a seasoned global MedTech executive and former President of Medtronic's Americas Region, and Brian Shea, who oversees healthcare investments and deal origination as Head of Origination at Aon Advantage Funds. Genau led a $7B business unit at Medtronic and brings deep expertise in scaling medical technologies and guiding commercial strategy. Shea offers a valuable perspective at the intersection of finance, healthcare, and technology. "We're thrilled to elevate Ralph to the Chairman role and honored to welcome Mike and Brian to our Board during this pivotal moment in BrainScope's evolution," said Laurie Silver, CEO of BrainScope. "Ralph has been an invaluable advisor as we've developed and launched our next-generation EEG-based Large Neural Model platform. Mike's leadership in MedTech and Brian's strategic investment insight will be beneficial as we scale commercially, drive clinical innovation in expanded markets, and bring in new investment partners. To reflect our expanded capabilities, we've also launched a new website showcasing our deep learning technology and broader brain health mission." "It's exciting to take on the role of Chairman at such a transformative time," said Ralph Terkowitz. "BrainScope is turning groundbreaking science into meaningful real-world impact, and has demonstrated success in using qEEG coupled with computational neuroscience as a diagnostic tool to aid in assessment of many neurological conditions including stroke, concussions, and early Alzheimer's. I look forward to helping the team expand this potentially groundbreaking opportunity." About BrainScope BrainScope is a leading neurotechnology company with over 15 years of experience advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope's initial commercial product remains the only point-of-care technology that objectively assesses head-injured patients for both brain bleeds and concussions. The company is now advancing novel biomarkers for early Alzheimer's detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and brain fog. For more information, please visit View source version on Contacts Media Contact: Kissy BlackLotos Nile615-310-1894info@ Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Business Wire
a day ago
- Business Wire
BrainScope Expands Board and Launches Advanced Deep Learning Platform to Enhance Brain Health Insights
BETHESDA, Md.--(BUSINESS WIRE)--BrainScope®, a leader in AI-enabled EEG technology for brain health assessment, today announced the launch of its next-generation deep learning platform. BrainScope developed and has commercialized the first FDA-cleared AI/machine learning medical device in the field of neurology. Building on that foundation in machine learning, BrainScope's new capabilities enhance its ability to deliver fast, objective, and clinically actionable insights across brain health conditions including concussion, stroke, and early Alzheimer's detection. BrainScope's new Large Neural Model platform brings many of the breakthroughs of Large Language Models to bear on EEG data, eliminating the need for specialized qEEG interpretation. The integration of deep learning into BrainScope's proprietary platform marks a major leap forward in automated EEG analysis. BrainScope's new Large Neural Model platform brings many of the breakthroughs of Large Language Models (LLMs) to bear on EEG data, eliminating the need for specialized qEEG interpretation. This novel and proprietary approach enhances BrainScope's first-in-class machine learning foundation, with the potential to significantly expand its utility across clinical care, research, and biopharma by enabling the development of more refined biomarkers to support precision-driven clinical trial recruitment, early diagnosis, personalized treatment, and improved patient outcomes. To help guide the company as it expands its clinical program and commercial activities, BrainScope has announced key updates to its Board of Directors. Ralph Terkowitz, who has served on BrainScope's Board since 2023, has been elected Chairman. A former General Partner at ABS Capital Partners, Terkowitz brings decades of experience helping technology companies grow and scale. He also serves on the Board of The 10,000 Brains Project and is Co-Chairman of The Robert Packard Center for ALS Research at Johns Hopkins. In his expanded role, Terkowitz will guide BrainScope's continued growth and adoption of its AI-powered brain health platform. Also joining the Board are Mike Genau, a seasoned global MedTech executive and former President of Medtronic's Americas Region, and Brian Shea, who oversees healthcare investments and deal origination as Head of Origination at Aon Advantage Funds. Genau led a $7B business unit at Medtronic and brings deep expertise in scaling medical technologies and guiding commercial strategy. Shea offers a valuable perspective at the intersection of finance, healthcare, and technology. 'We're thrilled to elevate Ralph to the Chairman role and honored to welcome Mike and Brian to our Board during this pivotal moment in BrainScope's evolution,' said Laurie Silver, CEO of BrainScope. 'Ralph has been an invaluable advisor as we've developed and launched our next-generation EEG-based Large Neural Model platform. Mike's leadership in MedTech and Brian's strategic investment insight will be beneficial as we scale commercially, drive clinical innovation in expanded markets, and bring in new investment partners. To reflect our expanded capabilities, we've also launched a new website showcasing our deep learning technology and broader brain health mission.' 'It's exciting to take on the role of Chairman at such a transformative time,' said Ralph Terkowitz. 'BrainScope is turning groundbreaking science into meaningful real-world impact, and has demonstrated success in using qEEG coupled with computational neuroscience as a diagnostic tool to aid in assessment of many neurological conditions including stroke, concussions, and early Alzheimer's. I look forward to helping the team expand this potentially groundbreaking opportunity.' About BrainScope BrainScope is a leading neurotechnology company with over 15 years of experience advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope's initial commercial product remains the only point-of-care technology that objectively assesses head-injured patients for both brain bleeds and concussions. The company is now advancing novel biomarkers for early Alzheimer's detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and brain fog. For more information, please visit
Hamilton Spectator
27-05-2025
- Hamilton Spectator
Abell Pest Control Celebrates the 100th Birthday of Ralph Abell, Second Generation Leader in Century Old Family Business
Toronto, Ontario, May 27, 2025 (GLOBE NEWSWIRE) — This month, Abell Pest Control proudly celebrates a remarkable milestone: the 100th birthday of Ralph Abell, a second-generation leader whose life and legacy are deeply woven into the fabric of the company. Founded in 1924 by his father, Earl Abell, in the basement and garage of their Toronto home, the business began as a modest pesticide manufacturing operation. Under Ralph's guidance and vision, it evolved into one of the most trusted names in pest control across Canada and beyond, a true Canadian success story built on family values, innovation, and service. From its earliest days, Abell Pest Control was founded on family, hard work, and a commitment to integrity. Ralph exemplified these principles. Known for his technical expertise and forward-thinking leadership, he championed a model of pest control that was quiet, effective, and people-focused. 'Ralph was a true pioneer in the pest control industry, ahead of his time in both service and how he treated people,' said Brett MacKillop, President of Abell Pest Control. 'He believed in doing things right, focusing on lasting solutions, and showing genuine respect for customers and team members. His values, innovation, integrity, and excellence still guide our business today.' As President of the Canadian Pest Management Association from 1972 to 1974, Ralph helped raise public awareness about the industry and the importance of using pesticides safely. He also worked closely with government officials to improve regulations and promote higher standards across the industry. Ralph joined the business full-time in 1940 as the first technician, having spent his childhood learning from his father, Earl Abell. His hands-on experience and natural understanding of the industry helped shape a unique perspective: that pest control isn't just about eliminating problems, it's about keeping families and communities safe. In 1960, Ralph Abell became President, leading the company into a period of expansion and modernization. 'Pest control is essential to public health and well-being,' said MacKillop. 'From preventing the spread of disease to safeguarding food supplies, our work remains necessary. Over the past century, the industry has advanced from basic chemicals to science-driven, sustainable solutions. What has endured is the unwavering commitment to public health and safety, a legacy instilled by Ralph Abell.' Happy 100th birthday, Ralph! About Abell Pest Control: Founded in 1924, Abell Pest Control is a proudly Canadian-owned and operated company that has been providing trusted pest management services across the country. With a long history of protecting customers and their patrons, Abell is committed to delivering exceptional service to both homes and businesses nationwide, available 24/7. Committed to innovation, Abell Pest Control offers cutting-edge technology-driven solutions for pest prevention and management, ensuring the highest standards of service. Abell values partnerships and is dedicated to giving back to the industries it serves, maintaining a strong network of alliances to better support its customers. Learn more about Abell by visiting or following them on social media for pest control tips on Facebook and Instagram .
